We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





AstraZeneca's COVID-19 Vaccine Is World’s Leading Candidate and May Deliver Results Earlier, Says WHO

By HospiMedica International staff writers
Posted on 29 Jun 2020
The experimental COVID-19 vaccine from AstraZeneca (Cambridgeshire, England) is possibly the world’s leading candidate and the most advanced in terms of development, according to the chief scientist of the World Health Organization (WHO).

“Certainly in terms of how advanced they are, the stage at which they are, they are I think probably the leading candidate,” WHO chief scientist Soumya Swaminathan told a news conference. More...
“So it’s possible they will have results quite early.”

A report by Reuters has stated that AstraZeneca had already commenced large-scale, mid-stage human trials of the vaccine developed by researchers at University of Oxford and recently signed its 10th supply-and-manufacturing deal. According to Swaminathan, Moderna’s COVID-19 vaccine candidate was “not far behind” that of AstraZeneca and among more than 200 candidates, 15 had entered clinical trials.

“We do know that Moderna’s vaccine is also going to go into phase three clinical trials, probably from the middle of July, and so that vaccine candidate is not far behind,” said Swaminathan. “But I think AstraZeneca certainly has a more global scope at the moment in terms of where they are doing and planning their vaccine trials.”

Swaminathan said that the WHO was in discussions with several Chinese manufacturers, including Sinovac, as well as with Indian researchers on potential vaccines and called for drugmakers to consider collaborating on COVID-19 vaccine trials.




Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
Desk Aneroid Sphyg
Diagnostix 750D+
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: Reusable catheter patients used 35 percent fewer antibiotics compared to their single-use only counterparts. (Photo courtesy of the University of Southampton)

Reusable Intermittent Catheters Reduce Antibiotic Use Without Increasing Urinary Tract Infections

Intermittent self-catheterization, used to empty the bladder several times a day, can leave patients vulnerable to recurrent urinary tract infections and repeated antibiotic use. Reliance on single-use... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.